Article Details
Retrieved on: 2024-04-02 13:59:29
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses how Senex Biotechnology's research, involving bioinformatics, highlights the effectiveness of CDK8/19 inhibitors for treating castration-resistant prostate cancer (CRPC), with the potential for non-toxic therapy.
Article found on: fox4kc.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here